ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,718.57
0.28%
US Tech 100
19,312.80
0.08%
다우존스 지수
42,124.65
0.15%
Bitcoin
62,898.46
-0.68%
Registration Strip Icon for default 무료로 등록하여 실시간 주식 시세, 대화형 차트, 실시간 옵션 플로우 등을 받아보세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Esperion Therapeutics Inc (ESPR)

  7. Esperion Therapeutics Inc (ESPR) 뉴스

ESPR

Esperion Therapeutics (ESPR)

Esperion Therapeutics Inc
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:ESPR
일자시간출처헤드라인심볼기업
2024/09/1905:12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ESPREsperion Therapeutics Inc
2024/09/1905:11Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ESPREsperion Therapeutics Inc
2024/09/1805:02Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ESPREsperion Therapeutics Inc
2024/09/1804:28Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ESPREsperion Therapeutics Inc
2024/09/1804:20Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ESPREsperion Therapeutics Inc
2024/09/0521:00GlobeNewswire Inc.Esperion to Participate in Upcoming 2024 Cantor Global Healthcare ConferenceNASDAQ:ESPREsperion Therapeutics Inc
2024/09/0321:00GlobeNewswire Inc.Esperion Secures Additional Commercial and Medicare Formulary Coverage for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe)NASDAQ:ESPREsperion Therapeutics Inc
2024/08/2621:00GlobeNewswire Inc.Esperion to Participate in Upcoming H.C. Wainwright 26th Annual Global Investment ConferenceNASDAQ:ESPREsperion Therapeutics Inc
2024/08/2105:03Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ESPREsperion Therapeutics Inc
2024/08/2004:50Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ESPREsperion Therapeutics Inc
2024/08/1305:33Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ESPREsperion Therapeutics Inc
2024/08/1305:08Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ESPREsperion Therapeutics Inc
2024/08/1220:21Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ESPREsperion Therapeutics Inc
2024/08/1219:00GlobeNewswire Inc.Esperion Reports Second Quarter 2024 Financial Results and Provides a Business UpdateNASDAQ:ESPREsperion Therapeutics Inc
2024/08/1218:47IH Market NewsU.S. Futures Steady as Markets Await Key Inflation Data, Oil Prices ClimbNASDAQ:ESPREsperion Therapeutics Inc
2024/08/0805:30GlobeNewswire Inc.Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:ESPREsperion Therapeutics Inc
2024/08/0605:34Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ESPREsperion Therapeutics Inc
2024/07/2521:00GlobeNewswire Inc.Esperion to Report Second Quarter 2024 Financial Results on August 12NASDAQ:ESPREsperion Therapeutics Inc
2024/07/2421:00GlobeNewswire Inc.Esperion to Participate in Upcoming BTIG Biotech ConferenceNASDAQ:ESPREsperion Therapeutics Inc
2024/07/1921:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ESPREsperion Therapeutics Inc
2024/07/1921:29Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ESPREsperion Therapeutics Inc
2024/07/1804:22Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ESPREsperion Therapeutics Inc
2024/07/1804:11Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ESPREsperion Therapeutics Inc
2024/07/1621:00GlobeNewswire Inc.New Digital First Marketing Campaign from Esperion Alerts Patients with Uncontrolled LDL Cholesterol to the “Lipid Lurkers” Inside Their ArteriesNASDAQ:ESPREsperion Therapeutics Inc
2024/06/2820:00GlobeNewswire Inc.Esperion Announces Monetization of European Royalties and Concurrent Payoff and Termination of Existing Revenue Interest FacilityNASDAQ:ESPREsperion Therapeutics Inc
2024/06/1904:19Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ESPREsperion Therapeutics Inc
2024/06/1904:09Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ESPREsperion Therapeutics Inc
2024/05/2905:16Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ESPREsperion Therapeutics Inc
2024/05/2505:18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ESPREsperion Therapeutics Inc
2024/05/2505:14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ESPREsperion Therapeutics Inc
 검색 관련기사 보기:NASDAQ:ESPR

최근 히스토리

USOTC
BNPQY
BNP Paribas (QX)
AMEX
SPY
SPDR S&P 500
NASDAQ
MSFT
Microsoft
COIN
SOLUSD
Solana
USI
USTECH100
US Tech 100
COIN
DOGEUSD
Dogecoin
USOTC
RHHBY
Roche (QX)
NYSE
CVX
Chevron
NASDAQ
AMZN
Amazon.com
NYSE
MCD
McDonalds
NASDAQ
AAPL
Apple
FX
USDEUR
US Dollar vs Euro
CCOM
US30
US 30
USOTC
DTEGY
Deutsche Telekom (QX)
SPI
SP500
S&P 500
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유